Stereotaxis has filed a prospectus with the United States Securities and Exchange Commission (SEC) regarding the resale of 108.87 million shares of common stock by selling stockholders. The filing provides the regulatory framework for the proposed transaction, detailing the terms under which the shares may be offered and sold. This move allows existing stockholders to liquidate their holdings without the company issuing new equity or raising fresh capital.

Transaction Details

The prospectus specifically covers the resale of 108.87 million shares. These shares are being offered by selling stockholders, meaning the proceeds from the sale will go to these individuals or entities rather than to Stereotaxis. The document serves as a formal registration statement required under securities laws to facilitate the resale of these previously issued securities on the public market.

Regulatory Compliance

The filing with the SEC ensures that the resale of the shares complies with federal securities regulations. It provides necessary transparency to potential investors regarding the source of the shares and the identity of the selling parties. The prospectus includes standard disclosures about the risks associated with the investment and the mechanics of the resale process.

Key Figures

The registration of these shares does not indicate a change in Stereotaxis' business operations or financial strategy, but rather a mechanism for current shareholders to sell their stakes.

Stereotaxis has completed its acquisition of Robocath, integrating the French company’s robotic technologies into its own platform to advance solutions for electrophysiology, interventional cardiology, and neurointerventions. The move strengthens Stereotaxis’s position as a leader in robotic technologies across the full spectrum of endovascular procedures, combining complementary expertise to accelerate the development of next-generation systems.

Robocath, founded in 2009 by Philippe Bencteux, specializes in smart robotic solutions for cardiovascular and neurovascular diseases. Its R-One system, which has obtained CE and NMPA certifications, boasts a technical procedure success rate of over 98% with no major adverse cardiovascular events. The technology is currently in use across Europe and China.

The integration is expected to yield commercial synergies and expand the addressable market for both companies. Philippe Bencteux, Robocath Founder and CEO, highlighted the opportunity to accelerate innovation and expand global reach, bringing robotic solutions to more physicians and patients worldwide.

David Fischel, Stereotaxis Chairman and CEO, emphasized that the addition of Robocath’s technology and team accelerates Stereotaxis’s strategy and enhances its technological leadership. The combined platform aims to support new strategic opportunities and improve patient care with robotic precision and safety.

Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions. The company focuses on delivering robotic systems, instruments, and information solutions for the interventional laboratory, enhancing productivity, connectivity, and intelligence in the operating room.